Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial

Authors
Category Primary study
Year 1999
This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The authors concluded that the GPIIB/IIIA blocker, tirofiban, can reduce complications in patients with acute coronary syndromes after angioplasty at no increase in cost.
Epistemonikos ID: 54246a788c9901677d6d01ee8792014cff66ccc8
First added on: Apr 19, 2023